| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2020: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
A search for HTLV-1 proviral load in the intraocular fluid of HTLV-1-associated uveitis (HAU) revealed that in some cases the proviral load in the intraocular fluid was higher than in the peripheral blood and in some cases was lower, and was also higher in non-HAU uveitis occurring in HTLV-1 carriers. Soluble interleukin 2 receptor (sIL-2R) in intraocular fluid in adult T-cell leukemia (ATL), HTLV-1 carriers, and non-carriers was significantly higher in intraocular inflammation (+) than in intraocular inflammation (-) and significantly higher in ATL intraocular invasion but not in choroidal invasion. Analysis of the clinical features of HAU revealed a significantly higher frequency of granular vitreous opacities than in controls and a higher incidence of HTLV-1-associated myelopathy (HAM) in HAU patients than in asymptomatic carriers.
|
